title: Current barriers, challenges and opportunities for the development of effective STI vaccines: point of view of vaccine producers, biotech companies and funding agencies.
abstract: Several barriers limit the development of vaccines against sexually transmitted diseases (STIs). Critical scientific information is missing that makes the feasibility and the likelihood of success of vaccines against genital herpes, chlamydia, gonorrhea and trichomonas uncertain: the immunity induced by natural infection is absent or imperfect which seriously limits the capacity to define the types of immune responses that an effective vaccine must induce. Reliable animal models are lacking and a number of crucial clinical questions are still unanswered about the goal of these vaccines and definition of endpoints for clinical trials. In the absence of a clear recognition of the need for vaccines against these diseases, there is no motivation for public or private research and industry to invest in the development of vaccines against STIs. The STI burden should be evaluated not only in terms of mortality and morbidity, but also in terms of economic and psycho-social impact. A global public-private consortium could mobilize the joint efforts of all stakeholders involved in the research, development and implementation of STI vaccines of the public and private sectors; ensure that sufficient resources are applied to R&D of vaccines against these STIs; and provide the pull-push forces that are necessary to overcome the barriers to develop safe and effective vaccines against these diseases.
authors.affiliation: Dodet Bioscience, 6B rue de Verdun, 69300 Caluire et Cuire, France. Electronic address: betty.dodet@dodetbioscience.com.
authors.forename: Betty
authors.initials: B
authors.lastname: Dodet
mesh_terms: D035843:Biomedical Research; D001709:Biotechnology; D004345:Drug Industry; D006801:Humans; D055818:Public-Private Sector Partnerships; D012749:Sexually Transmitted Diseases / Q000517:prevention & control*; D014612:Vaccines
chemical_list: D014612:Vaccines
keywords: Correlate of protection; STI burden; STI vaccine development; Vaccine companies